search
Back to results

Evaluation of Lysine-Specific Demethylase 1

Primary Purpose

Hypertension

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Para-aminohippuric Acid
Angiotensin II
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional other trial for Hypertension

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age 18-65
  • mild to moderate hypertension
  • no other major illnesses
  • BMI < or equal to 40

Exclusion Criteria:

  • secondary illnesses
  • BMI > 40
  • taking 4 or more anti-hypertensive medications
  • BP >160/100 on screening exam
  • Alcohol intake >12 oz per week
  • Current smoking
  • Recreational drug use
  • use of birth control pills or contraceptive hormone shots

Sites / Locations

  • Brigham and Women's Hospital

Outcomes

Primary Outcome Measures

Evaluating for the mechanisms by which genetic variants in the LSD1 gene contribute to salt-sensitive hypertension and cardiovascular disease
The overall goal of this study is to expand on our preliminary findings by further evaluating in human subjects with hypertension, the mechanisms underlying the interactions between Lysine-Specific Demethylase 1 (LSD1), dietary sodium and salt-sensitivity. One objective is to test the hypothesis that in humans, LSD1 status modifies cardiovascular responses to changes in sodium intake. The effect of LSD1 genotype on vascular and cardiac function will be assessed by performing vascular (aortic compliance) and cardiac (diastolic relaxation and cardiac strain) studies on liberal and low sodium diets in 3 groups of hypertensive subjects. Additionally, we will test if salt sensitivity associated with LSD1 is related to impaired renal vascular response to dietary sodium and alterations in renal sodium excretion. This proposal will better define how LSD1 influences CV function and its interaction with sodium intake.

Secondary Outcome Measures

Full Information

First Posted
October 3, 2012
Last Updated
July 11, 2017
Sponsor
Brigham and Women's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01702688
Brief Title
Evaluation of Lysine-Specific Demethylase 1
Official Title
Evaluation of Lysine-Specific Demethylase 1 As An Epigenetic Regulator of Salt Sensitive Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Withdrawn
Study Start Date
July 2012 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Thank you for your interest in our Blood Pressure Research Study. The American Heart Association is sponsoring us to investigate why patients develop high blood pressure, atherosclerosis (hardening of the arteries), and heart disease. There are two parts of our research program. The first part is a screening visit. At this visit you will be given a brief physical exam and will be asked questions concerning your medical history. During the same visit you will have your blood drawn for routine screening and genetic testing. You will also be asked to collect a urine sample for routine screening. If the doctor finds that you are a healthy candidate you will be invited to participate in the second part of the study. During Phase II, we will perform physiological tests after you are placed on a low salt diet and again after you are placed on a higher salt diet. If you are on blood pressure medication, it may be necessary to discontinue taking your present medication for up to three months before beginning the study. Patients discontinuing their current blood pressure medication may be placed on a different blood pressure medication during this 'washout' period if necessary to maintain blood pressure at pre-study levels. Once your blood pressure medications are discontinued, you will be closely monitored. If you do not own a home blood pressure monitor, we will provide one for you to use during the study so that you can keep a daily record of your blood pressure readings. We will ask you to call us every three days to report your blood pressure readings. After you have stopped taking your medication, dietitians at the hospital will make you low salt meals to eat at home for about seven days. On the last day of the low salt diet, you will be asked to begin a 24-hour urine collection that you will bring with you when you are admitted to the hospital that evening. That morning, you will be required to come to the Center for Clinical Investigations (CCI) at Brigham and Women's Hospital for a one-hour test to check if your body is in the correct salt balance. You will return that evening to the CCI where you will be admitted for your study that will occur the next morning. On the morning of your low salt study, we will collect some blood samples. We will also take ultrasound pictures of your heart to see how salt and hormones affect the way your heart and blood vessels functions. These tests will last approximately 5 hours and you will be discharged around 2:00 PM. For the next 5-7 days, you will be placed on a liberal salt diet. During this diet period, you will eat all your own food, but we will give you some supplements to add to your meals. After 5-7 days on your liberal salt diet, on the morning of your second admission to the hospital, you will be asked to begin a final 24-hour urine collection. That morning, you will again be required to come to the CCI for a blood test, and you will return later that evening to the inpatient CCI where you will be admitted for your final overnight study. The same study that was done for the low salt diet will be repeated for the liberal salt study. You will be discharged at around 2:00 p.m. These studies will help to determine if you are salt-sensitive. In addition, we hope to learn more about the hormones that regulate your blood pressure and the genes responsible for regulating those hormones. You will be placed back on your initial blood pressure medication (if you are on any) and returned to your regular physician for care. We can also provide clinically relevant information to you.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Para-aminohippuric Acid
Other Intervention Name(s)
PAH
Intervention Description
Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated "PAH".
Intervention Type
Drug
Intervention Name(s)
Angiotensin II
Other Intervention Name(s)
AngII, AII
Intervention Description
Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
Primary Outcome Measure Information:
Title
Evaluating for the mechanisms by which genetic variants in the LSD1 gene contribute to salt-sensitive hypertension and cardiovascular disease
Description
The overall goal of this study is to expand on our preliminary findings by further evaluating in human subjects with hypertension, the mechanisms underlying the interactions between Lysine-Specific Demethylase 1 (LSD1), dietary sodium and salt-sensitivity. One objective is to test the hypothesis that in humans, LSD1 status modifies cardiovascular responses to changes in sodium intake. The effect of LSD1 genotype on vascular and cardiac function will be assessed by performing vascular (aortic compliance) and cardiac (diastolic relaxation and cardiac strain) studies on liberal and low sodium diets in 3 groups of hypertensive subjects. Additionally, we will test if salt sensitivity associated with LSD1 is related to impaired renal vascular response to dietary sodium and alterations in renal sodium excretion. This proposal will better define how LSD1 influences CV function and its interaction with sodium intake.
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age 18-65 mild to moderate hypertension no other major illnesses BMI < or equal to 40 Exclusion Criteria: secondary illnesses BMI > 40 taking 4 or more anti-hypertensive medications BP >160/100 on screening exam Alcohol intake >12 oz per week Current smoking Recreational drug use use of birth control pills or contraceptive hormone shots
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bindu Chamarthi, MD
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluation of Lysine-Specific Demethylase 1

We'll reach out to this number within 24 hrs